Skip to main content

Table 1 Demographics and clinical characteristics of patients with MRSA BSI

From: Everybody nose: molecular and clinical characteristics of nasal colonization during active methicillin-resistant Staphylococcus aureus bloodstream infection

Factor, n (%)

(n = 68)

Sex

 

 Male

41 (60)

 Female

27 (40)

Race/ethnicity

 

 Non-hispanic white

23 (34)

 Non-hispanic black

23 (34)

 Hispanic/latinos

19 (28)

 Asian

2 (3)

 Other/not reported

1 (1)

Age at time of infection

 

 18–54 years

18 (26)

 55–69 years

28 (41)

 ≥ 70 years

22 (32)

History of IV drug use

4 (6)

HIV

7 (10)

Admission source

 

 Homea

46 (68)

 NH/Rehab/LTACH

15 (22)

 Outside hospital

7 (10)

Prior hospital admission (90 days)

42 (62)

Length of hospital stay prior to BSI

 

 CO-MRSA

40 (59)

 HO-MRSA

28 (41)

Clonal complex

 

 CC5

28 (41)

 CC8

30 (44)

 Other

10 (15)

Frequent healthcare interaction

 

 Hemodialysis

14 (21)

Infusion centerb

14 (21)

 None

40 (59)

Presence of invasive devicec

51 (75)

Invasive procedures (missing = 1)d

25 (37)

Wound presente

35 (51)

Comorbiditiesf

 

 Myocardial infarction

11 (16)

 Congestive heart failure

18 (26)

 Peripheral vascular disease

11 (16)

 Cerebrovascular disease

11 (16)

 Dementia

8 (12)

 Chronic pulmonary disease

15 (22)

 Connective tissue disease

3 (4)

 Peptic ulcer disease

1 (1)

 Mild liver disease

4 (6)

 Diabetes (no complications)

18 (26)

 Diabetes with organ damage

11 (16)

 Hemi or paraplegia

7 (10)

 Moderate/severe renal disease

14 (21)

 Solid tumor

2 (3)

 Leukemia

1 (1)

 Lymphoma/multiple myeloma

10 (15)

 Moderate/severe liver disease

5 (7)

 Metastatic solid tumor

11 (16)

Charlson comorbidity index (CCI)

 

 0–3

13 (19)

 4–5

20 (29)

 6–8

22 (32)

 > 8

13 (19)

History of transplantg

8 (12)

History of MRSA colonizationh

19 (28)

Presumed source of MRSA BSI

 

 Peripheral IV

7 (10)

 Skin and soft tissue infection

14 (21)

 Pneumonia

5 (7)

 Diabetic foot infection

1 (1)

 Vascular access

15 (22)

 Sacral wound

4 (6)

Other/unknown sourcei

22 (32)

  1. IV intravenous, NH nursing home, Rehab rehabilitation facility, LTACH long-term acute care hospital, CO community-onset, HO hospital-onset, MRSA methicillin-resistant Staphylococcus aureus, BSI bloodstream infection, HIV human immunodeficiency virus
  2. a “Admission from home”: included nonmedical residences such as home, group homes, assisted living facilities, and homeless shelters
  3. b“Infusion center”: outpatient centers for chemotherapy, intravenous fluids, intravenous immunomodulators, and blood products
  4. c“Presence of invasive device”: included pacemaker, implantable cardioverter defibrillator (ICD), left ventricular assist device (LVAD), vascular access (excluding peripheral intravenous catheters), orthopedic hardware, nephrostomy, suprapubic catheter, ileal conduit, foley catheter, arteriovenous graft placement (AVG), percutaneous endoscopic gastrostomy (PEG) tube, or ostomy
  5. d“Invasive procedures”: included any invasive procedures or surgery occurring within 1 month before first positive blood culture for MRSA, excluding electroencephalogram (EEG), electrocardiogram (EKG), and transthoracic echocardiogram (TTE)
  6. e“Wound present”: presence of a chronic skin wound overlying the sacrum, limb, abdomen, or other body part
  7. f“Comorbidities”: as defined by the Charlson Comorbidity Index (CCI); refer to standard definitions for CCI
  8. g“History of transplant”: included solid organ and bone marrow transplant
  9. h“History of MRSA colonization”: any positive culture from urine, sputum, tissue, or nares with MRSA prior to the positive MRSA blood culture or a documented history of prior MRSA infection or colonization
  10. i“Other/Unknown source”: MRSA infection from urinary source, osteomyelitis, surgical site infection, spinal infection, septic arthritis or cardiac device infection, or an unknown/not reported source
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us